Lineage Cell Therapeutics
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lineage Cell Therapeutics
EY’s M&A Firepower report predicts very active M&A activity for medtechs in 2021, driven by diagnostics and digital health, but with some headwinds remaining.
2020 has kicked off with a major European biotech deal that will see the Italian conglomerate Angelini take over Switzerland's Arvelle which is on the verge of getting EU approval for an anti-epilepsy drug licensed from SK Bio that got the green light in the US two years ago.
Myovant's Orgovyx was just approved by the US FDA for prostate cancer and could be approved soon for two women's health indications.
Virta Health’s digital health approach combines remote monitoring and customized advice to better manage type 2 diabetes.
- Drug Delivery
- Gene Therapy, Cell Therapy
Drug Discovery Tools
- Other Names / Subsidiaries
- Asterias Biotherapeutics, Inc.
- BioTime Acquisition Corp.
- BioTime, Inc.
- Cell Cure Neurosciences Ltd.
- Embryome Sciences
- ES Cell International Pte Ltd
- LifeMap Sciences, Inc.
- OncoCyte Corporation
- ReCyte Therapeutics